… trial evaluating the use of nivolumab (240 mg IV Q2 weeks) +/- ipilimumab (1mg /kg IV Q6
weeks) in patients (pts) with advanced/relapsed type B3 thymoma or thymic carcinoma, after …

… that nivolumab could be a potential option more than routine standard of care in refractory
type B3 thymoma or thymic … Our efficacy figures are in line with other available treatments in …

… We report the efficacy and safety results of the combination … in patients with advanced type
B3 thymoma and thymic … -PD-1 drugs (ie, nivolumab, pembrolizumab, and avelumab) and two …

… in the same patient population, the anti-PD-1 nivolumab did not achieve the same efficacy
… In the CAVEATT study 32 pre-treated patients (27 thymic carcinoma, 3 thymoma B3, 2 mixed…

… thymic malignancies are rare cancers, the efficacy and safety … for previously treated type B3
thymoma and thymic carcinoma, … PFS of nivolumab monotherapy was met in 35% of patients. …

… and of patients with completely resected type B2 or B3 tumors … months in 32 patients with
cisplatin pre-treated thymoma (26). … II trial tested nivolumab as second line in patients with TC. …

… Currently, combination therapy of Nivolumab and the anti-CTLA4-antibody … recurrent B3
thymoma or thymic carcinoma in the NIVOTHYM trial [13]. In the trial cohort receiving Nivolumab …

… Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic
carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial. ESMO Open 2023, 8, …

… This review identified 19 trials evaluating 335 advanced thymic carcinoma patients. … In
the nivolumab trial, two patients (13 %) were reported with serious irAEs requiring hospital …

… in patients with advanced thymoma treated with at least one prior standard therapy. Of the 7
patients with B1–B3 thymoma, … to investigate the efficacy and safety anti PD-1/PD-L1 drugs. …